August 2016

Safety Related Changes

Eviplera (300 mg tenofovir disoproxil fumarate/200 mg emtricitabine/25 mg rilpivirine) should not be coadministered with rilpivirine unless required for dose adjustment (e.g. with rifabutin).

Humira (adalimumab (rch)) is now indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.

Nolvadex (tamoxifen citrate) is now indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

Revlimid (lenalidomide) is now indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au